003017 大洋生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)3.1155.0188.1727.18512.581
总资产报酬率 ROA (%)1.9953.2745.6015.3799.774
投入资产回报率 ROIC (%)2.2383.7006.2415.90711.011

边际利润分析
销售毛利率 (%)19.02318.08413.82219.42824.426
营业利润率 (%)6.7626.1225.59410.12814.994
息税前利润/营业总收入 (%)6.5444.8795.61910.12015.215
净利润/营业总收入 (%)7.1905.4397.6298.93913.505

收益指标分析
经营活动净收益/利润总额(%)86.26695.71761.62867.87881.520
价值变动净收益/利润总额(%)-2.2283.4955.07513.5661.637
营业外收支净额/利润总额(%)0.041-19.804-3.028-4.186-1.447

偿债能力分析
流动比率 (X)1.2621.5381.5232.3423.482
速动比率 (X)0.9901.1841.2571.8323.134
资产负债率 (%)37.03934.81434.68127.9140.220
带息债务/全部投入资本 (%)27.09523.80522.47419.16812.007
股东权益/带息债务 (%)259.805308.124329.963410.636717.650
股东权益/负债合计 (%)169.987187.237188.341258.241353.984
利息保障倍数 (X)-29.694-21.11929.75125.39534.993

营运能力分析
应收账款周转天数 (天)22.43521.03117.56514.91415.143
存货周转天数 (天)75.25966.70256.94666.01753.449